Dr. Baliga's 'Podkasts for Curious Docs'

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI.   🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again.   📚 Published in JAMA, presented at #ESC2025 🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial

Dr. Baliga's 'Podkasts for Curious Docs'

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expanding role in cardiometabolic HFpEF 🫀 #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure

Dr. Baliga's 'Podkasts for Curious Docs'

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️.   🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates — but will it move the needle on outcomes?   #AFib #StrokePrevention #RemoteMonitoring #ECG #Cardiology #RCT #JAMA #DigitalHealth #Geriatrics 🧓📉

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠.   📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most.   📝 Editorial: Recommends shared decision-making 🤝 & individualized rhythm monitoring. 📚 A potential shift in post-ablation care.   🔗 #AFib #Anticoagulation #EPTrials #CardioTwitter #StrokePrevention #JAMA...

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)?   💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75)   🧠 Key Takeaway: Routine screening isn’t broadly warranted—but targeted testing in high-risk AMI patients may be the smarter path forward.   📊...

Dr. Baliga's 'Podkasts for Curious Docs'

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. 💬 Let’s rethink how we label, risk-stratify, and treat.   📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine...

Dr. Baliga's 'Podkasts for Curious Docs'

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨   #Leadership #Philosophy #History #Confucianism

Dr. Baliga's 'Podkasts for Curious Docs'

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5%. No serious adverse events. And yes — better gait speed, handgrip strength, and quality of life too. This is how we shift from survival ➡️ functional independence in aging populations. 🙌 👇 Would you apply this model...

Dr. Baliga's 'Podkasts for Curious Docs'

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)?   📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p=0.031) — even in the absence of clinical heart failure.   🌍 Consistent across trials and countries. Most benefit seen in patients <75 years. 📚 This could shift guidelines for a large overlooked population.   🔗 Read more in The Lancet (Aug...

Dr. Baliga's 'Podkasts for Curious Docs'

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%).   💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices. 👩‍⚕️ Signals of potential harm in women and STEMI subgroups raise questions, not answers. 📉 Should guidelines change? Or should practice just evolve?   #Cardiology...